Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Drug Name | Mobocertinib |
| Trade Name | Exkivity |
| Synonyms | TAK-788|TAK788|AP32788|AP-32788|AP 32788 |
| Drug Descriptions |
Exkivity (mobocertinib) inhibits EGFR and ERBB2 (HER2), with selectivity for mutant forms including EGFR exon 20 insertions, potentially resulting in growth inhibition in EGFR or ERBB2-mutant cancer cells (PMID: 33632775). Exkivity (mobocertinib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations after disease progression on platinum-based chemotherapy (FDA.gov). |
| DrugClasses | EGFR Inhibitor (Pan) 61 HER2 Inhibitor 41 |
| CAS Registry Number | 1847461-43-1 |
| NCIT ID | C126752 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Ado-trastuzumab emtansine + Mobocertinib | Ado-trastuzumab emtansine Mobocertinib | 0 | 0 |
| Alisertib + Mobocertinib | Alisertib Mobocertinib | 0 | 0 |
| Bevacizumab + Mobocertinib | Bevacizumab Mobocertinib | 0 | 0 |
| Cetuximab + Mobocertinib | Cetuximab Mobocertinib | 0 | 0 |
| Mobocertinib | Mobocertinib | 0 | 2 |
| Mobocertinib + Sapanisertib | Mobocertinib Sapanisertib | 0 | 0 |
| Mobocertinib + Trametinib | Mobocertinib Trametinib | 0 | 0 |
CKB BOOST